Ignite Creation Date:
2024-05-06 @ 12:16 PM
Last Modification Date:
2024-10-26 @ 12:56 PM
Study NCT ID:
NCT03719898
Status:
WITHDRAWN
Last Update Posted:
2021-01-05
First Post:
2018-10-16
Brief Title:
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Sponsor:
Fox Chase Cancer Center
Organization:
Fox Chase Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-12-06
Start Date Type:
ACTUAL
Primary Completion Date:
2020-03-18
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-06-16
Completion Date Type:
ACTUAL
First Submit Date:
2018-10-16
First Submit QC Date:
October 24 2018
Study First Post Date:
2018-10-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-01-04
Last Update Post Date:
2021-01-05
Last Update Post Date Type:
ACTUAL